OS Therapies Inc., a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company will provide a pre-recorded presentation for conference participants and engage in meetings with institutional investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 264920) on September 03, 2025, and is solely responsible for the information contained therein.